New York Patent of the Month – October 2024
ARMGO Pharma, Inc. has introduced a breakthrough treatment for congenital RYR1-related myopathy, a debilitating skeletal muscle disorder caused by dysfunctional calcium regulation in muscle cells. This pioneering pharmaceutical composition features a crystalline form of 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid hemifumarate, specifically engineered to address the underlying calcium leak in RyR1 channels.
The innovation leverages precise molecular design to stabilize defective ryanodine receptor (RyR1) channels, restoring their ability to regulate calcium release within skeletal muscle. This stabilization is crucial for enhancing muscle contractions, reducing fatigue, and improving overall muscle function in affected individuals. Administered orally in gastro-resistant tablet form, the treatment offers a convenient and effective solution to manage the disorder’s symptoms.
What sets this therapy apart is its precision. Traditional treatments for myopathies often focus on symptomatic relief, overlooking the cellular-level dysfunctions driving disease progression. ARMGO’s targeted approach directly addresses the root cause by repairing RyR1 channel leaks, ensuring that calcium levels within muscle cells are maintained at optimal levels. This innovative method represents a significant leap forward in treating RYR1-related myopathy.
Additionally, the drug’s crystalline form ensures exceptional stability and bioavailability, crucial for maintaining consistent therapeutic efficacy. Rigorous testing of its thermal and structural properties has confirmed its robustness, ensuring reliable performance under physiological conditions.
ARMGO Pharma’s novel treatment not only provides hope for those living with RYR1-related myopathy but also opens doors to potential applications in other calcium-regulation disorders. With this development, the company is redefining therapeutic possibilities, offering patients a chance to reclaim muscle strength and significantly improve their quality of life. This breakthrough underscores ARMGO’s commitment to pioneering solutions for rare and challenging conditions.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
